<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01146808</url>
  </required_header>
  <id_info>
    <org_study_id>AAAB8413</org_study_id>
    <secondary_id>IN-US-103-0158</secondary_id>
    <nct_id>NCT01146808</nct_id>
  </id_info>
  <brief_title>Adefovir Plus Vaccination in Transplant Patients Without Hepatitis B That Receive a Core Antibody Positive Liver</brief_title>
  <official_title>Prevention of de Novo Hepatitis B Infection With Adefovir Dipivoxil (ADV) and Hepatitis B Vaccination in HBsAg Seronegative Recipients of Liver Grafts From Hepatitis B Core Antibody Positive (HBcAb+) Donors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Columbia University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Columbia University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to evaluate the efficacy of adefovir (ADV) in preventing
      de novo Hepatitis B in patients who receive Hepatitis B core antibody (HBcAb) positive grafts
      but who are not Hepatitis B Surface antigen (HBsAg) positive prior to transplant (Hepatitis B
      naive patients). The second objective is to evaluate the efficacy of accelerated vaccination
      with Hepatitis B in inducing innate immunity, thereby obviating the need for life-long
      antiviral therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will conduct a prospective, open-label study of Hepatitis B naive patients
      who received HBcAb + livers and adefovir prophylaxis post-transplant. At one year to 18
      months following transplantation, all study patients will then be vaccinated with standard
      Hepatitis B vaccine at double dose on a monthly basis for three months, at which point they
      will be tested for Hepatitis B surface antibody (HBsAb). Any study patients that have
      developed a sufficient antibody response (HBsAb &gt;500 IU) will be given the option to
      discontinue anti-viral treatment in a monitored setting.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Development of de Novo Hepatitis B Infection After Transplant With a Core Antibody Positive Liver</measure>
    <time_frame>Standard of care visits post-transplant for 2 years</time_frame>
    <description>Determined by hepatitis B serologies and viral load.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients With a Sustained Hepatitis B Surface Antibody Titer &gt; 500 IU/mL Prior to and After Vaccination</measure>
    <time_frame>12-18 months post transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Patients Who Develop de Novo Hepatitis B Infection Post ADV Withdrawal, Which Will be Assessed at 6 Months Post Withdrawal</measure>
    <time_frame>Six months after hepatitis B vaccination (2 years post transplant)</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Hepatitis B</condition>
  <condition>Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>ADV plus hepatitis B vaccination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adefovir dipivoxil and hepatitis B vaccination: All subjects will receive adefovir 10mg po daily, or adjusted for renal function and an option for Hepatitis B vaccination, double dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adefovir dipivoxil and hepatitis B vaccination</intervention_name>
    <description>Adefovir 10mg po daily, or adjusted for renal function and option for Hepatitis B vaccination, double dose</description>
    <arm_group_label>ADV plus hepatitis B vaccination</arm_group_label>
    <other_name>Hepsera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recipients who do not have evidence of hepatitis B surface antigen, regardless of
             HBcAb and HBsAb status, who:

               1. received liver transplantation with hepatitis B core antibody positive (and HBsAg
                  negative) grafts,

               2. received adefovir treatment post transplantation, and

               3. who have not reached the 18 month post transplantation time period.

        Exclusion Criteria:

          -  Recipients with hepatitis B surface antigen positivity prior to liver transplant.

          -  Grafts from hepatitis B surface antigen positive patients.

          -  Previous intolerance to ADV therapy

          -  Recipients with pre-transplant creatinine &gt; 1.6 mg/dL

          -  Patients younger than 21 years of age

          -  Patients who are pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert S Brown, Jr, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Liver Disease and Transplantation at Columbia University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Liver Disease and Transplantation at Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/livertransplantation.html</url>
    <description>Liver Transplantation information from the NIH</description>
  </link>
  <reference>
    <citation>Wachs ME, Amend WJ, Ascher NL, Bretan PN, Emond J, Lake JR, Melzer JS, Roberts JP, Tomlanovich SJ, Vincenti F, et al. The risk of transmission of hepatitis B from HBsAg(-), HBcAb(+), HBIgM(-) organ donors. Transplantation. 1995 Jan 27;59(2):230-4.</citation>
    <PMID>7839446</PMID>
  </reference>
  <reference>
    <citation>Saab S, Chang AJ, Comulada S, Geevarghese SK, Anselmo RD, Durazo F, Han S, Farmer DG, Yersiz H, Goldstein LI, Ghobrial RM, Busuttil RW. Outcomes of hepatitis C- and hepatitis B core antibody-positive grafts in orthotopic liver transplantation. Liver Transpl. 2003 Oct;9(10):1053-61.</citation>
    <PMID>14526400</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 16, 2010</study_first_submitted>
  <study_first_submitted_qc>June 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2010</study_first_posted>
  <results_first_submitted>January 25, 2017</results_first_submitted>
  <results_first_submitted_qc>January 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 15, 2017</results_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vaccination</keyword>
  <keyword>Immunocompromised Host</keyword>
  <keyword>Antiviral Agents</keyword>
  <keyword>Drug Resistance, Viral</keyword>
  <keyword>Resource Allocation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Adefovir</mesh_term>
    <mesh_term>Adefovir dipivoxil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ADV Plus Hepatitis B Vaccination Group</title>
          <description>This group included recipients of Hepatitis B Core Antibody Positive livers who are negative for Hepatitis B infection.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ADV Plus Hepatitis B Vaccination Group</title>
          <description>This group included recipients of Hepatitis B Core Antibody Positive livers who are negative for Hepatitis B infection.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Development of de Novo Hepatitis B Infection After Transplant With a Core Antibody Positive Liver</title>
        <description>Determined by hepatitis B serologies and viral load.</description>
        <time_frame>Standard of care visits post-transplant for 2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ADV Plus Hepatitis B Vaccination Group</title>
            <description>This group included recipients of Hepatitis B Core Antibody Positive livers who are negative for Hepatitis B infection.</description>
          </group>
        </group_list>
        <measure>
          <title>Development of de Novo Hepatitis B Infection After Transplant With a Core Antibody Positive Liver</title>
          <description>Determined by hepatitis B serologies and viral load.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients With a Sustained Hepatitis B Surface Antibody Titer &gt; 500 IU/mL Prior to and After Vaccination</title>
        <time_frame>12-18 months post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ADV Plus Hepatitis B Vaccination Group</title>
            <description>This group included recipients of Hepatitis B Core Antibody Positive livers who are negative for Hepatitis B infection.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients With a Sustained Hepatitis B Surface Antibody Titer &gt; 500 IU/mL Prior to and After Vaccination</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Patients Who Develop de Novo Hepatitis B Infection Post ADV Withdrawal, Which Will be Assessed at 6 Months Post Withdrawal</title>
        <time_frame>Six months after hepatitis B vaccination (2 years post transplant)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ADV Plus Hepatitis B Vaccination Group</title>
            <description>This group included recipients of Hepatitis B Core Antibody Positive livers who are negative for Hepatitis B infection.</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Who Develop de Novo Hepatitis B Infection Post ADV Withdrawal, Which Will be Assessed at 6 Months Post Withdrawal</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ADV Plus Hepatitis B Vaccination Group</title>
          <description>This group included recipients of Hepatitis B Core Antibody Positive livers who are negative for Hepatitis B infection.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Robert S. Brown Jr., MD, MPH</name_or_title>
      <organization>Columbia University Medical Center</organization>
      <phone>(212) 305-3839</phone>
      <email>tt2103@columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

